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INTRODUCTION 
Chronic liver disease is considered as a global issue today as it 
often leads to liver cirrhosis and hepatocellular carcinoma, which is 
initially characterized by fibrosis in the liver. Liver fibrosis
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occurs due to 
a longstanding damage to the liver, that is associated with excess  
accumulation of extracellular connective tissue protein. 
        The main etiologies of hepatic fibrosis include longstanding  
infection of hepatitis B and Hepatitis C , alcohol drinks, and non-
alcoholic steatohepatitis of liver (NASH).The accumulation of 
extracellular connective tissue protein will distort hepatic architectures by 
forming excessive fibrous tissue and resulting in the development of 
hepatic nodules. Once the nodules have been developed, the condition is 
defined as cirrhosis.  
Liver biopsy, eventhough being an invasive method, is still 
regarded as standard criterion for determining the stage of fibrosis. As 
there are so many obstacles, complication and expensive cost of the 
invasive method, numerous studies have proposed a diagnostic method 
for fibrosis staging using non-invasive methods. 
        Liver fibrosis can be measured by FibroScan significantly, in 
consistent with or equal to the liver staging made by liver biopsy. The 
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diagnostic accuracy of FibroScan2 is higher in comparison to biomarkers 
to evaluate the stage of liver fibrosis. 
FibroScan offers some advantages compared to liver biopsy since it 
is a rapid and painless test with less interpretation error. Evaluation of 
liver fibrosis using non-invasive method may also be done by APRI 
score. 
          By comparing some of simple laboratory markers, the methods can 
predict those patients with chronic hepatic disease who are progressing to 
fibrosis, thereby, treatment can be initiated earlier to control further 
complications. 
      The primary aim of the study is to compare the  predictive value of 
aspartate aminotransferase to platelet ratio index (APRI) with Fibro Scan 
as a confirmatory tool for predicting liver fibrosis in patients with chronic 
hepatitis B and C infection . 
 
 
AIMS AND OBJECTIVES 
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AIMS AND OBJECTIVES 
Comparison of the accuracy between aspartate aminotransferase 
(AST) to platelet count ratio index(APRI) value to Fibroscan to predict  
fibrosis of liver in patients with chronic Hepatitis B and/or C patients .                   
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REVIEW OF LITERATURE 
HEPATITIS B INFECTION 
About 4000 lakhs people in the world are infected with Hepatitis B 
virus chronically. Most of these individual won’t experience 
complications, but around 15% to 40% would have  sequelae as cirrhosis 
or hepatocellular carcinoma and die prematurely. 
        The rate of acute hepatic failure3 secondary to Hepatitis B virus is 
declining, so the number of cases for liver transplantation for chronic 
hepatic failure. This decline is mostly due to wider vaccination programs 
along with use of antiviral therapy. 
        From a global perspective, global implementation of early-life 
vaccination programs among high- and intermediate-risk countries would 
ultimately had the greater effect on liver disease–associated mortality 
among near future generations. 
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EPIDEMIOLOGY 
Geographic Distribution and Source of Infection 
The prevalence of HBV infection vary considerably  worldwide. 
• In regions that are highly endemic, as those of Southeastern Asia, 
China, and most regions of Africa, 9% of the people were chronic 
HBV carriers, thus, the lifetime risk of infection varies from 65% 
to 75%. In the above areas, the mother to child transmission and 
horizontal spread amongst the adolescents are the prime source of 
transmission. Approximately,65% of the  population globally are 
residing in areas of highly endemic  HBV infection. 
• Regions of intermediate risk would include Southern Europe,  
Japan, India, Soviet Union1, and  north Africa. In these areas, the 
risk of acquiring the infection is between 30% and 60%. Horizontal 
transmission involves a broad age range, but neonatal exposure 
also tends to be common. 
• Areas of lower prevalence includes Northern America, West 
Europe, Australia, where the risk of acquiring Hepatitis B infection 
is around 20% and the transmission is predominantly horizontal 
amongst young adults.  
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INFECTIVITY 
HBV is transmitted primarily by percutaneous and through 
exposure of mucous membrane to infected body fluids. Hepatitis B Virus 
is 50 to 100 times more infectious as HIV and 15 times more infectious as 
Hepatitis C. HBeAg seropositivity  points toa the fact that there is a  
higher risk for perinatal transmission,  following needle prick  exposure 
and among the  household contacts. 
       Detection of HBV DNA by newer sensitive techniques like PCR in 
body fluids, other than stool that is not mixed with blood1. Eventhough, 
HBV replication occur primarily in liver cells, presence of  viral 
intermediates and those of virally proteins in sites, like adrenal gland, 
colon, skin serves as extrahepatic reservoir for infectious source of virus. 
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VIROLOGY 
      HBV is a small DNA virus belonging  to the family Hepadnaviridae. 
Hepatitis B virus is a small virus which has a DNA genomic structure and 
a double-stranded structure. The genome consists of around 4 open 
reading frames, a  design where several other genes overlap and also 
utilises the same DNA for encoding different proteins of virus. 
     
      The important 4 viral gene components include the Core gene, 
Surface gene, X, and the polymerase genes. 
 Core[C] genome1 helps in encoding the core nucleocapsid 
component, necessary for packaging of virus and for HBeAg 
production . 
 Surface [S] gene aids in encoding the pre-S1, pre-S2, and also S 
protein 
 X gene encode a  X protein, with transactivating properties and 
plays an   prime  role  in hepatocellular carcinoma formation. 
 
  
 
 
 Polymerase genome  has a large open reading frame . It helps in 
encoding a protein with those functions that are crucial for DNA 
replication(including priming, RNA
polymerase)1
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- and DNA-dependent DNA 
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VIRAL REPLICATION 
      HBV being   a DNA virus, process of  replication occur primarily  
with the aid of an RNA intermediate and also require an viral reverse 
transcriptase enzyme. The Mutation rate is much higher for Hepatitis B1 
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virus in comparison to other DNA viruses (around 1010 to 1020 point 
mutations per day). . 
      Due to genomic overlap, some of these silent mutations in 1 ORF 
(e.g., the polymerase gene) might  result in substitution of amino acid in 
overlapping Open reading frame. 
      Replication of hepatitis B virus usually begin with encapsidation of 
viral RNA. HBV DNA polymerase tends to  reverse transcribe these 
RNA into a negative-strand HBV DNA, thus in turn serve as templates 
for positive-strand synthesis resulting in a partially dsDNA 
 genome. 
      Concurrent with synthesis of HBV DNA,  nucleocapsid also 
undergoes maturation, however,through a different mechanism, 
interacting with S protein initiating assembly of virus in the 
[ER]endoplasmic reticulum. S protein is synthesized in the endoplasmic 
reticulum, and monomers aggregate excluding the host membranous  
proteins which ultimately buds into lumen as subviral particles.Once 
formed, HBsAg tends to undergo glycosylation in the Golgi apparatus 
and the endoplasmic reticulum. 
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       Noninfectious viral particles (filamentous as well as spherical forms) 
are secreted in greater number in comparison to matured virions. These 
subviral particles may exceed virions by a variable factor of 102 to 1051 
in number and will accumulate up to concentrations of several hundred 
micrograms per ml. of serum.  
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GENOTYPES 
      Genomic classification depending on comparisons of genomes had 
showed  10 genotypes and numerous subtypes of HBV.  
• Genotype A ,the prominant genotype seen in United States, North 
Europe. 
• Genotypes B / C are mostly confined to East Asia and also the Far 
East populations. 
• Genotype D were found globally, however with  highest  
prevalence in the Middle East, and Southeast Asia1 . 
•  Genotype E is prevalent in West Saharan areas. 
• Genotype F noted in Central parts of America. 
• Genotype G had been noted in the France. 
• Genotype H prevails in parts of Mexico. 
• Genotypes I and J were the most recently discovered and had been 
observed in Ryukyu Islands in Japan and Vietnam respectively. 
 
      The strongest clinical association appears to be : 
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(1) Seroconversion of HBeAg would occur in patients with HBV 
genotype B prior to genotype C. 
(2) The therapy response with interferon (IFN) is better amongst 
genotypes A and B than with C and D .The viral genotypes might have an 
effect on the hepatocellular carcinoma1 . 
 
Clinical Associations 
• Seroconversion of HBeAg: hepatitis B < C virus 
• Response to Interferon-α treatment: A > B ≥ C > D 
• Frequency of Precore or core promoter mutant: genotypes A and F 
• Progression of Hepatic disease :B < C 
• Evolving chronic hepatic failure: A < non-A 
• Risk of Hepatocellular carcinoma: hepatitis B > C. 
 
MUTATIONS 
      Most of mutations in genomic structure are identified by comparing 
sequences  of nucleotide with that of wild-type HBV that doesn’t  alter 
the amino acid sequence in a particular ORF2. 
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Hepatitis B Surface Antigen Gene 
      HBsAg gene mutants results due to a primary mutation in the HBsAg 
gene or due to a mutation in DNA polymerase gene during antiviral 
nucleoside therapy . 
      Once mutation appears, mutated virions would usually becomes 
selected immunologically as dominant form of virus. Mutations in the 
HBsAg gene between positions of amino acid  124 to 147 are important  
as this region of  HBsAg gene include the major “a” epitope which  binds 
to neutralizing antibody to HBsAg (anti-HBs). The mutation leads to 
failure for  detection of  HBsAg by commercial assays, depending on 
binding to anti-HBs, to failure of neutralization by hepatitis B 
Immunoglobulin1 or of vaccination. 
      HBsAg gene-mutant HBV infection  is accompanied by anti-HBc 
detection. Serum levels of HBV DNA can  be varied as they are in 
HBsAg carriers .Mutants need to be distinguished from “occult” hepatitis 
B cases, which are linked to cryptogenic cirrhosis and increased  HCC 
risk. 
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      Even in occult HBV infection, HBsAg negative persons may have 
detectable HBV DNA levels in the serum. Some of them Might not have 
evidence of    serologic markers of infection (e.g., anti-HBc). 
      Occult infection is primarily due to  active suppression of replication 
of virus with a result, HBV DNA is present in low levels (<200 IU/mL) 
by the action of host immune system. 
 
PATHOGENESIS
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      The severity of HBV-associated hepatic involvement is due to 
severity of  immunologic response to the hepatitis B virus by the host. 
Cellular and humoral responses are necessary for complete clearance with 
a long-term protection for  reinfection. Pathogenesis of disease is mainly 
due to cellular immune response1.  
 
     Antigen-specific T-cell response induction would happen in lymphoid 
organs, where  the host T cells will attack viral antigens .  The above 
process tends to  result in  maturation and expansion of T cells that are  
specific for viral antigens followed by  movement to the liver, for  
performing their effector function completely. 
      During an acute Hepatitis B infection, cell of innate immune system 
and hepatic-infiltrating Hepatitis B-specific CD8+ cells would clear HBV 
DNA molecules  from  liver with the help of  noncytopathic mechanisms 
mediated by cytokines. 
      Cytotoxic T lymphocyte aids in  T-cell receptor binding to the 
peptide-Major histocompatibility complex whose binding on liver  
surface will help  in the infected cell being directly killed and release of 
the potential antiviral cytokines by already activated Cytotoxic T 
lymphocyte1 . 
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      Appropriate presentation of viral peptides is required for MHC class 
II–restricted CD4+ T cell recognition. Antiviral cytokines is produced by 
the CD4+ cells which helps in neutralization of antibody production 
thereby , limiting spread of virus during infection and also aids in 
prevention of reinfection. 
 
NATURAL HISTORY 
Various  phases of Hepatitis B  infection observed are: 
 Immune tolerance, 
 immune clearance, 
 Inactive carrier state, and 
 Reactivation . 
      These consecutive phases are  most likely apparent in patients with 
acquisition of hepatitis B early in life. 
 The immune tolerance phase which is the earliest phase to be 
recognized in patients with infection history at birth or in early 
years of life, characterized by: 
 Positivity of HBeAg, 
 Higher HBV DNA levels (≥107 IU/mL)3, 
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 Lower to normal levels of serum aminotransferases, 
 Minimal necroinflammation or fibrosis in the liver.     
 Rates of HBeAg loss during this phase are low. Perinatal 
transmission of HBeAg is one of several potential mechanisms in 
the immunetolerance phase. 
 After several decades only ,the immune active phase  of  HBV 
infection often begins characterized by: 
 Elevated serum aminotransferase levels, 
 Lower HBV DNA than in the immune tolerance phase, 
 Histologic evidence of chronic hepatitis  . 
      This apparent immunology is triggered by activation against HBV are 
poorly understood, though CD8+ CTL-involving  lysis of infected liver 
cells has been  occurred . 
 
      Host immune system continues to put effort against the virus that may 
result in seroconversion of  HBeAg (HBeAg loss with the development of 
anti-HBe in the serum). HBeAg seroconversion may not always indicate 
quiescent disease, as much  as 30% of those who undergo HBeAg 
seroconversion enter into a next phase of active disease that is caused by 
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the selection of HBeAg-negative mutants (precore mutation, core 
promoter mutantion, or a combination of both). 
      At least half of these people demonstrate huge fluctuations in HBV 
DNA and aminotransferase levels every year, and recognition of both 
active disease and exclusion of the inactive HBsAg carrier state may need 
serial assessments of  serum Hepatitis B DNA and aminotransferase 
levels. 
 Most patients who undergo HBeAg seroconversion, however, enter 
a third phase (inactive HBV carrier stage), which is characterized 
by 
 Normalization of serum ALT 
 Low (<2000 IU/mL) hepatitis B DNA levels  
 Hepatic necrotic inflammation with fibrosis subside gradually. 
 The inactive HBsAg carrier phase lasting for  a lifetime, some 
patients might develop reactivation, which may occur 
spontaneously due to loss of immunological control over viral 
replication or can be as a consequence of immunosuppressive 
drug therapy. 
 Reactivation is defined by the  higher levels of Hepatitis B  
DNA level reappearance  in serum, with or without 
seroreversion of HBeAg, and is often seen with a noticeable 
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rise in levels of serum ALT.  In 20% of cases. if the immune 
active phase of hepatitis B remains untreated, we can anticipate 
cirrhosis to develop.  
     
       Various factors have been determined which increase the risk of 
Cirrhosis.  
 Elderly, 
 Male gender, 
 The state of fibrosis at the time of presentation,  
 Ongoing Hepatitis B replication.  
      Combined infection with HDV, Hepatitis C , or HIV, are prone for  a 
higher rate of developing  cirrhosis and HCC. With the development of  
cirrhosis ,major complications may occur: decompensation of liver and 
hepatocellular carcinoma.  
      The estimated annual frequency of developing liver 
decompensation in Hepatitis B-associated cirrhosis is 5% to 8%, whereas 
that of HCC is 2% to 4%. 
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Factors associated with an increased risk of HCC include: 
 male gender, 
 age 45 years or greater,  
 having a first degree  relative with HCC,  
 the presence of cirrhosis,  
 HBeAg positivity, 
 reversion from anti-HBe to HBeAg positivity,  
 increased HBV DNA levels regardless of the HBeAg state. 
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CHRONIC HEPATITIS B 
Acute Infection or symptomatic hepatitis history is usually absent 
in patients with chronic Hepatitis B infection. Once symptoms appear, 
fatigue is the most predominant symptom, others being poor appetite and 
malaise. 
  Patients remains asymptomatic at the time of reactivated hepatitis. 
Overlapping with cirrhosis, reactivation of hepatitis B  infection result in 
overt jaundice with signs of hepatic failure. Physical examination might 
be normal, or hepatomegaly, splenomegaly  can be present. In patient 
with decompensated cirrhosis, spider angiomas, icterus, ascites, and pedal 
edema are common.  
       Cirrhosis progression should always be borne in mind in the 
presence of hypersplenism, decrease in serum albumin (in the absence of 
nephropathy), or prolongation of the prothrombin time (PT) is noticed. 
Patients with advanced cirrhosis tend to have seum aspartate 
aminotransferase level higher than the alanine aminotransferase levels. 
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HISTOPATHOLOGIC FEATURES 
        Chronic Hepatitis B virus infection is usually marked by 
mononuclear cellular infiltration within the portal triad. Disruption of 
limiting plate of hepatocytes  occurs due to the periportal inflammation 
(also known as interface hepatitis), and at the interface among  
collagenous extensions from portal triads to hepatic parenchyma, 
inflammatory cells often are seen (known as active septa). 
          During the periods of reactivation of hepatitis B, active lobular 
inflammation is much more severe and remanant of them are present in 
acute viral hepatitis. 
.  
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     The light microscopy shows a charachteristic histologic feature, 
which is more specific for chronic hepatitis B infection is the appearance 
of ground-glass hepatocytes . This structural finding results due to  
collection of HBsAg particles (25 to 35 nm in diameter) in the dilated 
endoplasmic reticulum. Due to presence of high levels of cysteine in 
HBsAg, cells might tend to have a higher affinity for dyes, such as orcein, 
aldehyde fuchsin and Victorian blue. may also Hepatitis B   carriers 
might have ground glass hepatocytes, seen in around  5% cells. When 
they are present in excess, indicates active viral replication. 
DIAGNOSIS
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Following exposure to Hepatitis B viral infection, HBsAg usually  
appears after 2 to 10 weeks  but prior to increment of serum 
aminotransferase levels. In cases of self-limiting  acute hepatitis, HBsAg 
usually goes to undetectable levels following  4 to 6 months.Evolution to 
chronic HBV infection is indicted by the persistence of HBsAg for 
greater than 6 months. 
Coexistence of HBsAg and anti-HBs had been reported in 
approximately 10% to 20% of HBV carriers. The mechanisms most likely 
are due  to antibodies formed against HBsAg protein variants. 
Anti-HBc is usually detectable in chronic HBV infection. IgM 
class of anti-HBc usually appears following an acute infection and tends 
to persist for 4- 6 months following the infection and might also persist 
foryears . During chronic hepatitis B exacerbation, anti-HBc of IgM class  
becomes detectable and often used as surrogate for active viral 
replication. Anti-HBc of the IgG class is mostly seen in persons who 
progress to chronic infection. 
In low endemic areas such as the United States, anti-HBc in serum 
had been detected in 2% to 5% of the given population. Less than 5% of 
these patients are anticipated to have Hepatitis B  DNA levels  detectable 
in serum and therefore resulting in occult viremia. By contrast, isolated 
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anti-HBc are found in more than 50% of patients in highly endemic 
regions of the world, and 10% to 40% of patients with this finding might 
have Hepatitis B DNA detectable in serum. 
Anti-HBc isolated reactivity occurs in a clinical situation out of 
which, the most important to recognize is a false-positive result, which 
will be usually very weakly reactive and may not be reproducible.  
Failure to appreciate this, in patients who had no apparent exposure to 
HBV might result in needless consultation, inappropriate exclusion from 
vaccination program, and, rejection of the person from blood or organ 
donation. Such patients often have primary rather than anamnestic 
response to HBV vaccination1 .  
HBeAg is a viral protein seen at times of acute HBV infection. 
Once the serum aminotransferase levels peak ,the HBeAg reactivity 
usually disappears, and presence of persistence of HBeAg 3 months after 
the illness predictsa higher chance of chronic HBV infection.  
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The presence of HBeAg in HBsAg-positive carrier indicates active 
viral replication and maximum infectivity for intimate contacts.  
Serum Hepatitis B DNA values might be upto  1012-13 during the 
immune tolerance phase. Those patients with anti–HBe  have a reduced 
serum hepatitis B  DNA levels (105 to 108 copies/mL), with the values 
being highest found in elevated serum ALT levels. 
HBV DNA measurement can be done in serum using different  
qualitative or quantitative assays. The quantification of serum Hepatitis B  
DNA is mostly used to assess the need  for antiviral treatment and for 
monitoring  response in the treatment course.  
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 TREATMENT 
  Seven drugs are approved for the   treatment of chronic hepatitis  B 
infection. Five of these agents are nucleos(t)ide analogs which suppress 
HBV replication through an inhibitory effect on viral DNA polymerase. 
Nucleos(t)ide analogs have superior  oral bioavailability and a excellent  
safety record and are most potential inhibitors of viral replication than 
IFN-α agents. 
INDICATIONS FOR STARTING ANTIVIRAL THERAPY 
Goals 
The main treatment goals for  chronic hepatitis B patients are: 
• to forestall hepatic disease progression, 
• prevent late complications (fibrosis, liver failure, and 
hepatocellular carcinoma), 
• increase survival. 
       All these objectives are obtainable with long-term suppression of 
viral replication with either an IFN-α or nucleos(t)ide analogs. Our data 
suggests, among the overall patients with potentially treatable chronic 
hepatitis B infection ,only 10% are treated adequately. 
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NUCLEOSIDE AND NUCLEOTIDE ANALOGS 
Majority of  treatment-naïve” patients are treated with 1 or more 
nucleos(t)ide analogs rather than IFN. Between 70% and 85% of HBeAg-
positive patients would  become HBV DNA negative during the first year 
of treatment. A  group of patients might still have HBV DNA levels 
detectable in serum after several years of therapy with high-genetic-
barrier nucleos(t)ide analogs even though, clinical and biochemical 
response persists. The reason for this persistence of serum HBV DNA is 
not well understood, but the Hepatitis B  DNA levels are almost always 
below 3000 IU/mL, and drug-resistant mutants had not been 
demonstrated in this situation. 
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       The lack of adverse effects and good resistance profiles of the 
orally available antiviral agents are especially important properties as 
HBeAg seroconversion occurs slowly and requires treatment for an 
indefinite duration. Eventhough a  rapid decline in serum HBV DNA 
levels on nucleoside therapy occurs, only 20% to 25% of treated patients 
reach HBeAg seroconversion following  1 year of treatment. 
LAMIVUDINE 
        Due  to a high rate of resistant organisms , lamivudine is least 
considered as a first line therapy, except in persons who require only 
short-term therapy, such as those undergoing cancer chemotherapy. 
Prolonged lamivudine resistance had been associated with blunted 
histological response with much higher hepatitis flares. 
       Before commencement of antiviral therapy in patients who are 
born in endemic areas for hepatitis B, care to  be taken to inquire if 
antiviral therapy has ever been consumed  previously. In such patients, it 
is best not to use entecavir due to the high likelihood that prior exposure 
to lamivudine may predispose the patient to entecavir resistance. 
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ADEFOVIR DIPIVOXIL 
       Adefovir is licensed by the FDA after lamivudine became available 
and is  used frequently because it is an efficacious towards  lamivudine-
resistant HBV4 . Because of its limited potency, primary treatment failure 
(<1 log reduction in the serum Hepatitis B  DNA level at week 12) was 
present  in 30% of patients. 
ENTECAVIR 
       Entecavir, a nucleoside analog which is more potent than 
lamivudine or adefovir and  a  higher genetic barrier to resistance, which 
requires an additional DNA polymerase mutation superimposing on 
preexisting lamivudine resistant mutations. This situation appears to be 
rare in treatment-naïve patients, which explains the fact that resistance 
had been found in around 2% of treatment-naïve patients  continuous 
treatment for 5 years. 
       The long-term use of entecavir benefits includes progressive 
regression of fibrosis, features of cirrhosis reversal, and a reduced 
incidence of HCC. 
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TELBIVUDINE 
       Telbivudine , a nucleoside analog is a more potent drug  than 
lamivudine in all HBeAg-positive and HBeAg-negative patients. 
Following an year of treatment, around 30% of HBeAg positive patients 
are predicted to have genetic resistance.  
 
TENOFOVIR DISOPROXIL FUMARATE22 
       Tenofovir is chemically almost similar to adefovir, but had 
significantly higher rate of antiviral potency. High genetic barrier is 
responsible for making it more  resistant and a strong antiviral potency. 
Tenofovir is being used more frequently as a first-line therapy, in cases 
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where heavy exposure to lamivudine is present, known cases with 
lamivudine resistance, or following  its suboptimal response to adefovir5 . 
EMTRICITABINE 
       Emtricitabine  is morphologically  similar to lamivudine and tends 
to inhibit  Hepatitis B  DNA polymerase. FDA has not approved its for 
use in hepatitis B, neither alone nor in a combined tablet with tenofovir 
which is commonly used for HIV Infected patients. As it is structural 
similar to lamivudine, it’s resistance profile is also the same. 
HBV-HEPATITIS C  COINFECTION 
       HBV-Hepatitis C –coinfected patients as compared  to 
monoinfected patients usually have a higher degree of cirrhosis and grave 
prognosis. Before and after treatment is initiated  close monitoring is 
recommended. Authors in such instances, had  higher success in treating 
patients  and simultaneously in combintion of a nucleos(t)ide analog, 
pegylated IFN-α, and ribavirin. 
HEPATITIS C INFECTION 
       Chronic Hepatitis C , has the importance that it is the only type of 
chronic viral infection which can be completely cured by antiviral 
therapy. More importantly, successful  antiviral treatment helps in  
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preventing complications of many Hepatitis C  infected patients. As much 
as up to 80% of  Hepatitis C  genotype 1 infected patients who can 
tolerate treatment with pegylated interferon-α , ribavirin, and  also a first 
generation Hepatitis C  protease inhibitor achieves a higher sustained 
virologic response (SVR). The Chronic Hepatitis C infection leads to 
decompensated cirrhosis and hepatic carcinoma (HCC). 
VIROLOGY 
 
STRUCTURE: 
The Hepatitis C  virion that is an enveloped virus is 50 nm in 
diameter has been visualized by an electron microscopy. There are  two  
envelope  proteins, and a smoother outer layer. This layer has a 
“fishbone” configuration  with  a icosahedral symmetry.  
  
35 
 
       These enveloped proteins anchor  to  host cell–derived lipid 
bilayer envelope membrane which surrounds the nucleocapsid. The 
nucleocapsid consists  of multicopies of core protein forming  an  
icosahedral coat to encapsulate the genomic RNA. 
VIRAL REPLICATION AND LIFE CYCLE 
       Although T and B cells, a peripheral blood mononuclear cells, and 
also dendritic cells have reported to have supported  Hepatitis C  
replication, liver  which is the prime site of viral replication. Hepatitis C 
entry into the cell also involves the attachment of namely the envelope 
protein to cellular surface molecules21.  
       Apart from  this, human scavenger receptor  class B type 1 (SR-
B1) is also essential for the Hepatitis C  entry. 
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EPIDEMIOLOGY: 
        Different epidemiologic patterns of Hepatitis C infection has been 
present around the world. They are : 
(1) previous health care exposure  with a prevalence that peaks 
mostly in elderly; 
(2) another  is exposure through IV drug usage , where middle age 
group has a peak prevalence.  
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TRANSMISSION 
      Mode of transmission of Hepatitis C  is by two routes  
 Percutaneous (blood transfusion and needleprick inoculation) and 
 Nonpercutaneous (sexual contact and through perinatal exposure)6. 
PATHOGENESIS 
      Persistence of Hepatitis C  can be determined by: 
(1)inadequate induction of innate immune response,  
(2) evasion of the immune responses through various viral 
mechanisms, 
(3)sufficiency of induction or maintenance of any adaptive immune 
response, 
(4) viral quasispecies production 
(5) induction of immunologic tolerance20. 
        50% to 90% of persons with acute Hepatitis C  infection develop 
chronic hepatitis. In the group of patients where acute Hepatitis C  
resolves, an early T-cell response  has occured. Up to 20 years after 
resolution of infection  this response may be detected  and can contribute 
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to protection in  subsequent exposures to Hepatitis C .Though immune 
response plays an important  role in prevention of  viral persistence, in 
cases without the viral clearance,  immune response mediates the liver 
cell destruction and also cirrhosis. 
CHRONIC HEPATITIS C 
       Serum ALT levels tends to remain  elevated in chronic  Hepatitis C  
infected patients. Because of levels that commonly fluctuate, nearly 50% 
of patients may have normal alt level at any given point of time. 
 The Alanine transaminase  level 19 might remain normal for 20% of 
cases for prolonged periods of time, though transiently  elevations occur 
even in such cases. Persistently normal levels of alanine aminotransferase  
are very common among females , and they tend to be  associated with 
lower  levels of serum Hepatitis C  RNA and a lower inflammation with 
fibrosis on hepatic biopsy specimens. 
           Other symptoms that can be present are arthralgias, nausea, 
anorexia,  myalgias, mucosal dryness, and difficulty in concentration. The 
severity of the symptoms   would be directly proportional  to the severity 
of underlying hepatic  disease. 
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DIAGNOSIS 
   There are many molecular assays  and immunologic that can be 
used to detect or  infact monitor Hepatitis C  infection. In addition, any 
presence of anti-Hepatitis C  in the high titer in serum, that indicates 
exposure to this virus but can not differentiate in acute or chronic or 
resolved infection. Anti-Hepatitis C  usually is persistant for several years 
in patients even after resolution of this infection or Sustined Virologicl 
Response following  the antiviral therapy. 
Anti-Hepatitis C  titers can decline over time and can however 
become undetectable for 5 to 20 years even after Hepatitis C  clearance. 
Initially serologic assays can used for diagnosis. but for confirming 
infection the virologic assays is  required and monitoring the response to 
treatment or evaluating the immunocompromised patients. 
INDIRECT ASSAYS 
EIAs18 can detect antibodies which are against various Hepatitis C  
antigens. Three generations of  the EIAs are developed so far. The third-
generation EIAs are used to detect the antibodies against Hepatitis C  
core, NS3, NS4, and also NS5 antigens even within the 7th to 8th week 
after infection, with sensitivity and also specificity rates of 99% and with 
sensitivity. 
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DIRECT ASSAYS 
Quantitative, highly sensitive, and “real-time” Hepatitis C  RNA 
tests generally represent the state of art for determining  the Hepatitis C  
viremia in anti-Hepatitis C –positive persons. The lower limit for 
detection of many assays varies between 10 and 15 international units 
(IU)/ ml. Such  assays can have the  linear dynamic range between 1 to 7 
log10 IU/mL and these are preferable testing methods in practice.  
       Transcription-mediated amplification (TMA)17 are  extremely 
sensitive, though  the available assays aren’t usually quantitative in the 
test range of lower dynamic range. Advantages of this kind of high 
sensitive tests are positivity within the 1 to 3 weeks of acute infection and 
also detection of even low-level residual infection in the antiviral therapy. 
NATURAL HISTORY 
Once the chronic Hepatitis C  infection is established, spontaneous 
Hepatitis C  clearance seldom occurs. The Chronic Hepatitis C might lead 
to continuous liver damage which  results in liver cirrhosis or also HCC . 
Individual course of such liver disease is hugely variable. Patients may 
report symptoms like right abdominal discomfort or nausea with 
fatigue.Other symptoms include weight loss, myalgia, arthralgias. 
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All these clinical features are usually uncharacteristic and may not 
be associated with the severity of liver injury and are restricted to patients 
in advanced cirrhosis. More feared complication in chronic Hepatitis C  
infection is when liver-related mortality because of decompensated liver 
cirrhosis or even development of HCC. 
FACTORS ASSOCIATED WITH PROGRESSION 
For fibrosis progression, age is the very important  factor of risk in 
chronic Hepatitis C  infection. A long duration of infection is generally 
associated with higher stage of liver fibrosis. However, Hepatitis C  
infection during early childhood seems to follow a comparitively milder 
course.. 
TREATMENT 
      Before Hepatitis C  was identified, IFN-α monotherapy has been 
approved for chronic Hepatitis C treatment, then known as the non-A, 
non-B hepatitis. Substantial advances are made since the introduction of 
longer-acting pegylated formulations of IFN, prolonged treatment 
periods, and oral guanosine analog ribavirin. In 2011,  first DAAs, 
telaprevir and boceprevir, which are being  approved for treating  chronic 
Hepatitis C  genotype 1 infection, and during 2013, simeprevir yet 
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another protease inhibitor,  sofosbuvir, a nucleotide polymerase were also 
approved. 
Drugs 
INTERFERONS 
IFN-based regimens were the cornerstone of antiviral therapy  for 
Hepatitis C  infection since 1980s. IFNs are in general naturally occurring 
glycoproteins which exert a wide array of antiviral, antiproliferative, and 
also immunomodulatory effects. 
       Pegylated IFNs consists of IFN which is bound to a molecule of 
polyethyleneglycol (PEG) of various length. A large size of themolecule 
increases to a larger extent half-life of the IFN, hence allowing once a 
week dosage. 
     In the United States there are two pegylated IFNs which are licensed 
to use. The  40-kd peginterferon alfa-2a,  is used for a fixed dosage of 
180 µg per week. Next is the 12-kd peginterferon alfa-2b 16, that is 
prescribed in accordance with the patient’s body weight. The a dosage is 
1.5 µg/kg per week. Instead of the standard IFN which were used prior, 
the Pegylated IFNs are used resulting in a significant increase in SVR. 
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RIBAVIRIN 
Ribavirin, a oral guanosine analog which acts against DNA and 
RNA viruses. The ETR improves  whenever  ribavirin is used with IFN as 
a combination, the rate of relapse is lesser. 
     Ribavirin exhibits an synergistic effect  once administered as a  
combination  with IFN have been proposed, including: 
(1) alterations of the cytokine environment  from   type 2 T-helper 
cell (Th2) to a T helper 1immune response15; 
(2) intracellular guanosine triphosphate depletion  through  the 
mechanism of inhibition of the enzyme inosine monophosphate 
dehydrogenase (IMPDH); 
(3) HCV RNA-dependent RNA polymerase inhibition; 
(4)induces  mutagenesis during Hepatitis C  RNA replication, 
(5) increasing responsiveness to the type I IFNs. 
       Ribavirin usually is  tolerated, though it causes  hemolytic anemia. 
The dose  which  is administered  depending on  patient’s weight, and 
also the  Hb level has to be followed up during treatment.  
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DIRECT-ACTING ANTIVIRAL AGENTS 
Novel DAAs against Hepatitis C includes compounds which target 
HCV protease,  HCV NS5A protein and  HCV polymerase. These drugs 
inhibits HCV replication by interfering with  respective step in these 
HCV life cycle14. 
HCV protease inhibitors (“…previrs”) usually have high antiviral 
potency but may differ with respect to the development of its resistance. 
Most compounds show better responsive rates in HCV genotype 1b rather 
than in genotype 1a infection. 
Boceprevir and telaprevir are 2 protease inhibitors  approved by the 
FDA in 2011. Simeprevir  which became available in 2014 and the 
protease inhibitor faldaprevir have higher advantages as compared to 
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boceprevir and telaprevir in terms of dosage schedule and side effect 
profile. 
NS5A inhibitors (“…asvirs”) are characterized by high antiviral 
potency at picomolar doses. The cross-genotype efficiecy of these agents  
vary. Limited data on the efficiency of these drugs are only available in 
patients with these non-genotype 1 HCV. In 2014, Ledipasvir was the 
first NS5A inhibitor approved by FDA. 
       HCV polymerase inhibitors (“…buvirs”) 13can be categorized as 
nucleoside or nucleotide analog and non-nucleoside polymerase 
inhibitors. Non-nucleoside polymerase inhibitors are the weakest class of  
the compounds against HCV due to low barrier to resistance. Most drugs 
in this class are active mostly against HCV genotype 1b but to a lesser 
extent only against HCV genotype 1a. They are  developed to be used 
only as a combination with other DAAs, largely with protease inhibitors 
and NS5A inhibitors. 
       Nucleoside analogs are active with  all Hepatitis C  genotypes. 
Nucleoside analog resistant variants might emerge but they have very low 
fitness and do not rapidly expand. They cause a chain termination, 
thereby blocking HCV replication. 
  
 
The first approved nucleotide NS5B polymerase inhibitor was 
sofosbuvir.  
LIVER BIOPSY 
There is a wider range of risk of progressive liver  injury from the 
acquisition of HCV infection, as a score of  patients may show
degree of  progression after decades of infection and others may progress 
rapidly. Percutaneous liver biopsy could be used effectively to assess the 
patients . Other noninvasive methods to assess liver fibrosis
instead of liver biopsy. Live
other causes of liver disease.
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Several scoring systems  are  used  so as to quantify liver  injury to  
grade  inflammation and also stages of fibrosis. 
• Knodell and colleagues described a system called as Histology 
Activity Index (HAI). 
The different criteria used to classify include both periportal tract 
inflammation and necrosis(grading from 0 to 10), inflammation of lobules 
and necrosis (grades0 to 4), portal tract inflammation (0 to 4), and 
cirrhosis (0 to 4). This scoring system combines  both inflammation and 
fibrosis in 1score. 
• Scheuer created  a scoring system which separates grades from 
stages: Portal inflammation and interface hepatitis (0 to 4), lobular 
activity (0 to 4)8, and fibrosis stage (0 to 4).  
The Ishak system remains  a modification of the Knodell’s system. 
Histologic gradeis separated  from staging of cirrhosis. 
• Ishak’s fibrosis scores range between 0 to 6 (1 or 2, portal fibrotic 
expansion; 3 or 4, bridging fibrosis; 5 or 6, cirrhosis).  
• The METAVIR scoring system is  a popular scoring system in 
practice which is simpler than any other system. Inflammation 
being graded between 0 to 4 (none, mild, moderate, and severe), 
  
 
and fibrosis is staged between 0 to 4 (1, p
portal fibrosis with septa formation; 3, bridging fibrosis; 4, 
cirrhosis)9.  
       Though liver biopsy remains the diagnostic tool to grade 
inflammation and stage of fibrosis, disadvantages  of liver biopsy 
includes: 
(1) associated  pain in  some series,  hemorrhage or bile leak;
(2) expensive; 
(3) poor acceptance by the patient;
(4) interobserver  difference  during  interpretation of findings 
(5) inaccuracy in interpreting the results
48 
ortal fibroticexpansion; 2, 
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        Due to the disadvantages seen with  liver biopsy, many  
noninvasive tests had been in research. FibroSure , a noninvasive method 
to measure  fibrosis, that has sex and age adjustments, obtained from 
serum levels of α2-macroglobulin, haptoglobin, apolipoprotein A-1, 
GGTP, and total bilirubin.  
       Different techniques and instruments (e.g., transient elastography, 
acoustic radiation force impulse imaging, magnetic resonance 
elastography) are being available to determine liver stiffness. 
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The most frequently used system is transient elastography 
(Fibroscan) for  the  assessment of  liver elasticity, which is correlating 
inversely with  degree  of liver fibrosis. In a meta-analysis, the AUC  of 
Fibroscan to predict  fibrosis was 0.94.  
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        The AST-to-platelet ratio index (APRI) is used primarily in 
order to diagnose or exclude cirrhosis. During an initial evaluation, 
81% of cirrhotic patients were precisely  identified with  a score of 0.5 or 
less; however, the index may not help in  discriminating  among fibrosis 
of lower level.  
       There is an inverse relationship  between platelet count and 
Aspartate aminotransferase level with progression of liver fibrosis. 
During progression of cirrhosis and accompanying portal hypertension, 
results in increased sequestration of cells with lysis in spleen. 
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Thus, Hypersplenism being  the most commonest cause of platelet 
reduction related with cirrhosis and portal hypertension. Another cause is  
decreased production of thrombopoietin by the liver . The increased 
Aspartate aminotransferase level is due  to mitochondrial injury that is  
associated with the HCV infection. 
       Combining transient elastography along with serum markers will 
increase the accuracy of predicting fibrosis and cirrhosis and will avoid 
liver biopsy in many patients. It is, however, not indicated following a 
antiviral therapy, although histology usually improve significantly  over a 
period of  time following eradication of HCV 11. 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
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MATERIALS AND METHODS 
Study Centre  
Department of HEPATOLOGY, Madras medical college and Rajiv 
gandhi government general hospital, Chennai  
Duration of Study   
6 months 
Study Design 
Observational Study ( prospective and retrospective ) 
Sample Size 
100 patients 
Inclusion Criteria 
Patients with chronic hepatitis B or/and C virus infection without 
treatment aged 18 years or over. 
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Exclusion Criteria 
Patient with  
1.Coinfection with HIV 
2.Alcohol drink >30g/day within past 6 months 
3.Other etiologies of chronic liver disease 
4.Chronic renal failure 
5.Platelet count of 75,000/cu.mm. or less 
6.Bedridden patients. 
Data Collection and Methods 
Chronic  hepatitis B and/or C  patients  attending  Hepatology OP 
of RGGGH are subjected to detailed history taking , clinical examination 
and required investigations. 
Materials and Methods 
From Chronic hepatitis B and/or C patients attending the 
Hepatology department OPD, selected for clinical study as per 
inclusion/exclusion criteria the following data are collected: 
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-Demographic data  
-Medical history 
Patients are subjected to: 
-Platelet count 
-Liver function tests(Aspartate aminotransferase) 
-Fibroscan 
Product / procedure / investigation detail  
Platelet count 
Liver function tests(Aspartate aminotransferase) 
Fibroscan  
Analysis Plan 
SPSS, Epi INFO softwares 
Sponsorship  
No  
Conflict of interest 
None 
OBSERVATIONS AND RESULTS  
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OBSERVATION AND RESULTS 
FLOW CHART OF THE METHODOLOGY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TOTAL NUMBER 
OF CASES =100 
APPLYING THE 
INCLUSION AND 
EXCLUSION 
CRITERIA     COLLECTING 
RELEVANT DATA  
SUBJECTING TO  
INVESTIGATIONS 
    PLATELET COUNT 
    AST 
    FIBROSCAN 
  
CORRELATING 
FIBROSCAN VALUE 
WITH APRI SCORE 
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FREQUENCY OF AGE GROUP AMONG PATIENTS 
COLLECTED FOR OUR STUDY 
AGE_SCORE FREQUENCY PERCENT 
18-30 39 39.0 
31-40 28 28.0 
41-50 23 23.0 
51-60 10 10.0 
Total 100 100.0 
 
In our study, patients are collected among a wider range of age 
group from 18 years to 60 years who were diagnosed to have acquired 
Hepatitis B virus /and C infection .From our study, nearly 40% of  
patients are in their twenties. 
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BAR  DIAGRAM  DEPICTING THE AGE DISTRIBUTION IN 
OUR STUDY POPULATION 
 
 
 
 
          
39%
28%
23%
10%
0%
5%
10%
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35%
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FREQUENCY OF SEX DISTRIBUTION IN OUR STUDY SCORE
SEX 
MALE 
FEMALE 
Total 
 
Sex distribution 
males and females. 
BAR DIAGRAM SHOWING THE SEX DISTRIBUTION IN
 
44%
59 
FREQUENCY PERCENT
56 
44 
100 
appears to be almost equally distributed among 
OUR STUDY SCORE 
56%
 
 
56.0 
44.0 
100.0 
 
 
MALE
FEMALE
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TABLE SHOWING THE DISTRIBUTION OF HISTORY FOR 
WHICH PATIENTS WERE SUBJECTED TO BLOOD 
INVESTIGATIONS AND DETECTED AS HEPATITIS  
B / C INFECTION 
HISTORY FREQUENCY PERCENT 
ANTENATAL SCREENING 6 6.0 
EASY FATIGUE 7 7.0 
FEVER OF UN KNOWN 
ORIGIN 10 10.0 
INCIDENTALLY DETECTED 65 65.0 
LOSS OF APPETITE 12 12.0 
Total 100 100.0 
 
From the above table, we could identify that around 65% of 
patients were detected incidentally during routine health check ups or 
during blood donation. about 10% has history of loss of appetite, another 
12%  had history of fever. 
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6%
7%
10%
65%
12%
PIE CHART SHOWING THE CAUSE WHICH 
LEAD TO THE IDENTIFICATION OF HAPATITIS 
B /C INFECTION
ANTENATAL SEVERITY
EASY FATIGUE
FEVER OF UN KNOWN ORIGIN
INCIDENTALLY DETECTED
LOSS OF APPETTIE
  
TABLE SHOWS THE PERCENTAGE OF PATIENTS WHO 
ACQUIRED  THEIR INFECTION THROUGH 
BLOOD TRANSFUSION
NO 
YES 
Total 
 
Table provides the data that around 9% of our patients with 
hepatitis B/C in the 
transfusion. 
PIE CHART SHOWING PERCENTAGE OF 
PATIENTS WITH HISTORY OF BLOOD 
62 
BLOOD TRANSFUSION 
 FREQUENCY 
91 
9 
100 
study score acquired their infection through blood 
NO
92%
YES
8%
TRANSFUSION
 
PERCENT 
91.0 
9.0 
100.0 
 
  
TABLE SHOWS THE PERCENTAGE OF PATIENTS WHO HAD 
HISTORY OF  PREVIOUS SURGERY
PREVIOUS SURGERY
NO 
YES 
Total 
 
 From  above table, we could identify that around 20% of patients 
had history of previous surgery ,which might be the cause of acquiring 
Hepatitis B/C infection
PIE CHART SHOWING PERCENTILE OF PATIENTS WITH 
PREVIOUS SURGERY HISTORY
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 FREQUENCY 
81 
19 
100 
 
 
81%
19%
 
PERCENT 
81.0 
19.0 
100.0 
 
NO
YES
  
FREQUENCY OF PATIENTS
TATTOOING
NO 
YES 
Total 
 
In our study score, around 20% of patients had history of tattooing,
which could have been the source of Hepatitis B/C infection.
PIE CHART SHOWING 
PREVIOUS TATTOOING HISTORY
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 WITH HISTORY OF TATTOOING
 FREQUENCY 
81 
19 
100 
PERCENTILE OF PATIENTS WITH 
81%
 
PERCENT 
81.0 
19.0 
100.0 
 
 
 
 
NO
YES
  
FREQUENCY OF PATIENTS WHO HAVE HEPATITIS B / AND 
HBSAG 
HBSAG 
HCV 
BOTH 
Total 
 
Data collected from the above table shows about 74% patients had 
Hepatitis B infection, about 19% patients had 
coinfection present among 7% of patients.
19%
PIE CHART SHOWING FREQUENCY OF 
PATIENTS WHO HAVE HEPATITIS B / AND 
65 
HEPATITIS C INFECTION 
FREQUENCY PERCENT
74 
19 
7 
100 
Hepatitis C
 
74%
7%
C INFECTION
 
74.0 
19.0 
7.0 
100.0 
 infection with 
 
HBSAG
HCV
BOTH
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FREQUENCY OF PATIENTS DISTRIBUTED AMONG  
APRI SCORE 
APRI_SCORE FREQUENCY PERCENT 
<0.5 81 81.0 
0.5-1.5 9 9.0 
>1.5 10 10.0 
Total 100 100.0 
 
Among our study population, 81% patients fall within the APRI 
SCORE <0.5 denoting normal liver architecture, 9% patients comes 
under 0.5 -1.5 indicating ongoing or developing fibrosis, about 10% 
patients have their APRI SCORE >1.5 suggesting developed fibrosis 
/cirrhosis. 
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<0.5
81%
0.5-1.5
9%
>1.5
10%
FREQUENCY OF PATIENTS DISTRIBUTED 
AMONG APRI SCORE
  
FREQUENCY OF PATIENTS DISTRIBUTED 
FIBROSCAN_SCORE
<7 
7-11 
>11 
Total 
 
Among 100 patients in our study score, 72% has Fibroscan 
value < 7 implying normal liver architecture, with 14% having value >11 
indicating well developed fibrosis or cirrhosis with another 14% in the 
score in between with ongoing fibrosis.
 
14%
FREQUENCY OF PATIENTS DISTRIBUTED 
AMONG FIBROSCAN SCORE
68 
AMONG FIBROSCAN SCORE 
 FREQUENCY 
72 
14 
14 
100 
 
72%
14%
 
PERCENT 
72.0 
14.0 
14.0 
100.0 
 
 
<7
7 TO 11
>11
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CROSSTABULATION CORRELATING APRI SCORE WITH 
FIBROSCAN VALUES 
APRI_SCORE * 
FIBROSCAN_SCORE Crosstabulation 
FIBROSCAN_SCORE Total 
<7 7-11 >11 
Apri_Score 
<0.5 
Count 68 10 3 81 
% within 
FIBROSCAN_SCO
RE 
94.4% 71.4% 21.4% 81.0% 
0.5-
1.5 
Count 4 3 2 9 
% within 
FIBROSCAN_SCO
RE 
5.6% 21.4% 14.3% 9.0% 
>1.5 
Count 0 1 9 10 
% within 
FIBROSCAN_SCO
RE 
0.0% 7.1% 64.3% 10.0% 
Total 
Count 72 14 14 100 
% within 
FIBROSCAN_score 100.0% 100.0% 100.0% 100.0% 
Chi-Square = 60.257 ** P<0.001 
It is evident from the above table that out of 72 patients with 
normal liver architecture identified on Fibroscan , 68 patients are found to 
correlate well with APRI score. Similarly, out  of 14 ptients detected as 
having developed fibrosis or cirrhosis on Fibroscan , 9 patients correlate 
well with APRI score. 
It is clearly depicted that APRI score and Fibroscan values 
correlate well significantly, as the p value is < 0.001.  
 
  
BAR DIAGRAM CORRELATING APRI SCORE WITH
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CROSSTBULATION CORRELATING ASPARTATE 
MINOTRANSFERASE VALUES AND FIBROSCAN SCORE 
WITH APRI SCORE 
CORRELATION AST APRI 
FIBROSCAN
_ 
VALUE 
AST 
Pearson 
Correlation 1 .628
**
 .519** 
Sig. (2-tailed)  .000 .000 
N 100 100 100 
 
APRI 
Pearson 
Correlation .628
**
 1 .543** 
Sig. (2-tailed) .000  .000 
N 100 100 100 
FIBROSCAN_VAL
UE 
Pearson 
Correlation .519
**
 .543** 1 
Sig. (2-tailed) .000 .000  
N 100 100 100 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
It is  evident from the above table that as the AST value increases, 
APRI value also tends to rise. Correlation is considered significant at the 
0.01 level. 
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DIAGRAM CORRELATING AST VALUES WITH APRI SCORE 
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CROSSTBULATION CORRELATING ASPARTATE 
MINOTRANSFERASE VALUES AND FIBROSCAN VALUES 
WITH APRI SCORE 
APRI  SCORE N Mea
n 
Std. 
Deviati
on 
Std. 
Erro
r 
95% 
Confidence 
Interval for 
Mean Minim
um 
Maximu
m 
F 
VALU
E 
Lower 
Bound 
Upper 
Bound 
AST 
<0.5 81 21.94 8.00 0.89 20.17 23.71 10.00 46.00 
51.774
** 
0.5-1.5 9 39.33 17.94 5.98 25.54 53.13 20.00 64.00 
>1.5 10 167.10 136.63 43.21 69.36 264.84 52.00 508.00 
Total 100 38.02 60.58 6.06 26.00 50.04 10.00 508.00 
FIBROSCAN
_VALUE 
<0.5 81 5.61 1.93 0.21 5.19 6.04 3.20 11.70 
72.805
** 
0.5-1.5 9 7.72 2.60 0.87 5.72 9.72 4.10 11.80 
>1.5 10 16.64 6.45 2.04 12.03 21.25 7.30 27.30 
Total 100 6.91 4.28 0.43 6.06 7.76 3.20 27.30 
**P<0.001 
It is  evident from the above table that as the AST value increases, 
APRI value also tends to rise. Correlation is considered significant at the 
0.001 level. 
Values in the APRI score correlate well significantly with 
Fibroscan values.  
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CROSSTABULATION DEPICTING AGE WISE DISTRIBUTION 
OF APRI SCORE 
CROSSTAB 
AGE_SCORE 
Total 
18-30 31-40 41-50 51-60 
APRI SCORE 
<0.5 
Count 35 21 18 7 81 
% within 
AGE_SCORE 89.7% 75.0% 78.3% 70.0% 81.0% 
0.5-1.5 
Count 2 5 2 0 9 
% within 
AGE_SCORE 5.1% 17.9% 8.7% 0.0% 9.0% 
>1.5 
Count 2 2 3 3 10 
% within 
AGE_SCORE 5.1% 7.1% 13.0% 30.0% 10.0% 
Total 
Count 39 28 23 10 100 
% within 
AGE_SCORE 100.0% 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square = 10.023 P= 0.124 
The above table points out that there is no specific correlation 
between increasing age and APRI score. Thus, this cross tabulation has a 
p value of 0.124 which is considered as insignificant. 
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CROSSTABULATION CORRELATING APRI SCORE AND SEX 
DISTRIBUTION 
CROSSTAB 
SEX 
Total 
MALE FEMALE 
APRI_SCORE 
<0.5 
Count 43 38 81 
% within SEX 76.8% 86.4% 81.0% 
0.5-
1.5 
Count 8 1 9 
% within SEX 14.3% 2.3% 9.0% 
>1.5 
Count 5 5 10 
% within SEX 8.9% 11.4% 10.0% 
Total 
Count 56 44 100 
% within SEX 100.0% 100.0% 100.0% 
Pearson Chi-Square = 4.376   P= 0.112 
From the given table, it is depicted that there is no male to female 
significance among APRI score. As the Pearson’s Chi – square value is 
0.112, implies that sex distribution among APRI score is not significant. 
 
 
 
 
  
BAR DIAGRAM CORRELATING APRI SCORE AND SEX 
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CROSS TABULATION  CORRELATING HISTORY DURING 
DETECTION OF HBSAG/ HCV WITH APRI SCORE 
CROSSTAB 
HISTORY 
Total Antenat
al 
severity 
Easy 
fatigue 
Fever 
of un 
known 
origin 
Incidentally 
detected 
Loss of 
appetti
e 
APRI 
SCORE 
<0.5 
Count 6 4 8 52 11 81 
% within 
HISTORY 100.0% 57.1% 80.0% 80.0% 91.7% 81.0% 
0.5-1.5 
Count 0 1 1 7 0 9 
% within 
HISTORY 0.0% 14.3% 10.0% 10.8% 0.0% 9.0% 
>1.5 
Count 0 2 1 6 1 10 
% within 
HISTORY 0.0% 28.6% 10.0% 9.2% 8.3% 10.0% 
Total 
Count 6 7 10 65 12 100 
% within 
HISTORY 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square = 6.098  P= 0.636 
In the table given above, it is evident that history at the time of 
detection of HBSAG / HCV doesnot correlate with APRI score. Our p 
value was also 0.636 showing that it is insignificant in correlating history 
with APRI score. 
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CROSS TABULATION CORRELTING PLATELET COUNT 
WITH APRI SCORE 
CROSSTAB 
PLATELET_COUNT 
Total 
< One 
lakh 
One lakh - 
two lakh 
More than 
two lakh 
APRI SCORE 
<0.5 
Count 0 8 73 81 
% within 
PLATELET_COUNT 0.0% 47.1% 94.8% 81.0% 
0.5-1.5 
Count 2 5 2 9 
% within 
PLATELET_COUNT 33.3% 29.4% 2.6% 9.0% 
>1.5 
Count 4 4 2 10 
% within 
PLATELET_COUNT 66.7% 23.5% 2.6% 10.0% 
Total 
Count 6 17 77 100 
% within 
PLATELET_COUNT 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square = 51.012 **  P<0.001  
In our study score, around 73 patient had platelet value > 2,00,000 
cells / ul correlating with APRI score < 0.5.Similarly, we had 4 patient 
with thrombocytopenia correlating well with an APRI score of >1.5. 
From the given table, it is evident that as the platelet count reduces, 
the APRI score value increases. Since the p value appears to be <0.001, it 
is considered significant and well correlating.  
  
BAR DIAGRAM CORRELTING PLATELET COUNT WITH 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
< ONE LAKH
0%
33%
87%
81 
APRI SCORE 
 
ONE LAKH - TWO 
LAKH
MORE THAN TWO 
LAKH
47%
95%
29%
3%
24%
2%
>1.5
0.5-1.5
<0.5
 82 
 
CROSS TABULATION CORRELATING PRESENCE OF HBSAG 
AND / HCV WITH APRI SCORE 
CROSS TAB HBSAG HCV BOTH TOTAL 
APRI 
SCORE 
<0.5 
Count 62 14 5 81 
% within 
HBSAG 83.8% 73.7% 71.4% 81.0% 
0.5-
1.5 
Count 6 3 0 9 
% within 
HBSAG 8.1% 15.8% 0.0% 9.0% 
>1.5 
Count 6 2 2 10 
% within 
HBSAG 8.1% 10.5% 28.6% 10.0% 
Total 
Count 74 19 7 100 
% within 
HBSAG 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square = 4.628  P= 0.328 
From the above table, it is evident that patients with coinfection 
with HBSAg and HCV are more prone for fibrosis / cirrhosis, in 
comparison to  patients with HBSAg or HCV infection separately. 
Since the p value appears to be 0.328 , it predicts that this 
correlation between presence of HBSg / and HCV with APRI SCORE is 
not significant. 
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TABLE CORRELATING AGEWISE DISTRIBUTION WITH 
FIBROSCAN SCORE 
CROSSTAB 
AGE_SCORE 
Total 
18-30 31-40 41-50 51-60 
FIBROSCAN 
SCORE 
<7 
Count 34 23 12 3 72 
% within 
AGE_SCORE 87.2% 82.1% 52.2% 30.0% 72.0% 
7-11 
Count 3 2 6 3 14 
% within 
AGE_SCORE 7.7% 7.1% 26.1% 30.0% 14.0% 
>11 
Count 2 3 5 4 14 
% within 
AGE_SCORE 5.1% 10.7% 21.7% 40.0% 14.0% 
Total 
Count 39 28 23 10 100 
% within 
AGE_SCORE 100.0% 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square = 19.852 * P= 0.003 
In our study, the above table depicts that as the age increases , the 
incidence of fibrosis/ cirrhosis increases as evidenced by increased 
Fibroscan values (<11) 
The table had good correlation between agewise distribution and 
Fibroscan values, as the p value is significant (0.003).  
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CROSS TABULATION CORRELATING SEX DISTRIBUTION 
WITH FIBROSCAN VALUES 
CROSSTAB 
SEX 
Total 
MALE FEMALE 
FIBROSCAN 
SCORE 
<7 
Count 40 32 72 
% within SEX 71.4% 72.7% 72.0% 
7-11 
Count 8 6 14 
% within SEX 14.3% 13.6% 14.0% 
>11 
Count 8 6 14 
% within SEX 14.3% 13.6% 14.0% 
Total 
Count 56 44 100 
% within SEX 100.0% 100.0% 100.0% 
Pearson Chi-Square = 0.021  P= 0.990 
The table above shows that there is no significance between sex 
distribution and Fibroscan values , as confirmed by p value that is 0.990. 
 
 
 
 
  
BAR DIAGRAM  CORRELATING SEX DISTRIBUTION WITH 
 
 
 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
MALE
87 
FIBROSCAN VALUES 
FEMALE
71% 73%
15% 13%
14% 14%
 
>1.5
0.5-1.5
<0.5
 88 
 
CROSS TABULATION DEPICTING RELTIONSHIP BETWEEN 
HISTORY AT THE TIME OF DIAGNOSIS AND FIBROSCAN 
SCORE 
CROSSTAB 
HISTORY 
Total Antenatal 
Screening 
Easy 
fatigue 
Fever of 
un known 
origin 
Incidentall
y detected 
Loss of 
appettie 
FIBROSCAN 
SCORE 
<7 
Count 6 3 7 47 9 72 
% within 
HISTORY 100.0% 42.9% 70.0% 72.3% 75.0% 72.0% 
7-11 
Count 0 1 1 11 1 14 
% within 
HISTORY 0.0% 14.3% 10.0% 16.9% 8.3% 14.0% 
>11 
Count 0 3 2 7 2 14 
% within 
HISTORY 0.0% 42.9% 20.0% 10.8% 16.7% 14.0% 
Total 
Count 6 7 10 65 12 100 
% within 
HISTORY 100.0% 
100.0
% 100.0% 100.0% 100.0% 
100.0
% 
Pearson Chi-Square = 8.933  P= 0.348 
It is clear from the above table that there is no signifance in 
correlating history at the time of detection of HBSAg / HCV, as 
suggested by p value that is 0.348. 
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CROSS TABULATION CORRELATING PLATELET COUNT 
WITH FIBROSCAN SCORE 
CROSSTAB 
PLATELET_COUNT 
Total 
< One 
lakh 
One lakh 
- two lakh 
More than 
two lakh 
FIBROSCAN 
SCORE 
<7 
Count 2 6 64 72 
% within 
PLATELET_COUNT 33.3% 35.3% 83.1% 72.0% 
7-11 
Count 0 6 8 14 
% within 
PLATELET_COUNT 0.0% 35.3% 10.4% 14.0% 
>11 
Count 4 5 5 14 
% within 
PLATELET_COUNT 66.7% 29.4% 6.5% 14.0% 
Total 
Count 6 17 77 100 
% within 
PLATELET_COUNT 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square = 30.683 **  P<0.001 
In our study score, around 72 patients had platelet value > 2,00,000 
cells / ul correlating with FIBROSCAN SCORE <7. Similarly, we had 4 
patient with thrombocytopenia correlating well with an  FIBROSCAN 
SCORE >11. 
From the given table, it is evident that as the platelet count reduces, 
the FIBROSCAN value increases. Since the p value appears to be <0.001, 
it is considered significant and well correlating.  
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TABLE DEPICTING CORRELATION BETWEEN TYPE OF 
HEPATITIS VIRUS INFECTION (HBSAG / AND HCV) AND 
FIBROSCAN SCORE 
CROSSTAB 
HBSAG 
Total 
HBSAG HCV BOTH 
FIBROSCAN 
SCORE 
<7 
Count 56 13 3 72 
% within 
HBSAG 75.7% 68.4% 42.9% 72.0% 
7-11 
Count 9 3 2 14 
% within 
HBSAG 12.2% 15.8% 28.6% 14.0% 
>11 
Count 9 3 2 14 
% within 
HBSAG 12.2% 15.8% 28.6% 14.0% 
Total 
Count 74 19 7 100 
% within 
HBSAG 
100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square = 3.566  P= 0.468 
From the above table, it is evident that patients with coinfection 
with HBSAg and HCV are more prone for fibrosis / cirrhosis , in 
comparison to  patients with HBSAg or HCV infection separately. 
Since the p value appears to be 0.468 , it predicts that this 
correlation between presence of HBSg / and HCV with FIBROSCAN 
SCORE is not significant. 
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DISCUSSION 
This study was conducted as a prospective and retrospective 
observational study in patients attending Hepatology OPD at Madras 
Medical College and Rajiv Gandhi Government General Hospital. 
Sample size is 100. After getting the informed consent of the patients and   
their  attending close relatives, the patients were subjected to history 
taking, physical examination and relevant laboratory testing  and imging. 
These were done to identify the presence/ absence  of fibrosis /cirrhosis in 
the patient. 
A study by Hind I. Fallatah and Alyaa M. Fallatah et al also 
showed that APRI SCORE can be compared to fibroscan  for Assessment 
of Liver Fibrosis. 
        Another study by Wenwen Jin, Zhonghua Lin et al showed  
diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio 
(APRI) index for the assessing of hepatitis B-related fibrosis and found 
that it had almost equal sensitivity and specificity as Fibroscan in 
predicting fibrosis. 
Liver biopsy is presently the  standard  available for assessment of 
liver  fibrosis and necrotic inflammatory activity. Being  an invasive 
procedure subjected  to inter-observer variability and sampling error is up 
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to 33% of biopsies. Furthermore the biopsy might  have complications 
,for example  bleeding, pain or injury  of the neighbouring organs such as 
kidney, lung or colon.  
Due to these limitations, liver biopsy could not  be performed in 
such patients. The severity of Liver  fibrosis and the degree of liver 
damage in patients of chronic hepatitis B/ and C  acan be assessed using 
other simple noninvasive tests . 
Notable among these are fibrotest and hepascore which exhibit 
near diagnostic accuracy. 
An ideal non-invasive test for assessing liver fibrosis should be a 
simple, readily available, inexpensive, and must be accurate. AST/ ALT 
ratio was used for the diagnosis of cirrhosis. 
The aspartate aminotransferase-to-platelet count  ratio index 
(APRI), an index with limited expense and widespread availability, is a  
noninvasive alternative to liver biopsy in  detecting hepatic fibrosis. The 
objective of this study was to systematically review the performance of 
the APRI in predicting significant fibrosis and cirrhosis in hepatitis B 
/and C -related fibrosis. 
 
  
The combination of Fibroscan and APRI, provides a valuable 
approach for assessing
liver biopsy in patients without clear indication.
Liver enzymes are measured using a dimension clinical chemistry 
system (Flex Reagent Cartridge). APRI score can be  determined
the following equat
   
The limitation of the score is due to inability to identify various  
stages of fibrosis, it can however, only differentiate mild from significant 
fibrosis or mild/moderate from severe fibrosis.The interval between the 
diagnostic cut-offs 
patients tends to  remain unclassified. In these patients hepatic  biopsy  
needs to be performed for appropriate classification. 
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 hepatic  fibrosis. This can eliminate the need for 
 
ion : 
≤0.90 and ≥1.5 is the major  grey zone where the 
 
  using 
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LIMITATIONS OF THE STUDY 
A multi centric study with a large sample size and further  longer 
follow up is essential in order to assess the predictive power of these 
prognostication tools in a much more comprehensive manner. 
 
 
                                       
 
 
 
 
 
 
 
 
CONCLUSION 
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CONCLUSION 
From our study results, it could be concluded  that ASPARTATE 
AMINOTRANSFERASE –PLATELET COUNT RATIO INDEX (APRI) 
SCORE has sensitivity and specificity around 80-90% as comparable to 
Fibroscan scores in assessing  hepatic fibrosis in patients with chronic 
hepatitis B virus  / and C infection. 
      Hence, it can be used as a non-invasive tool in predicting cirrhosis 
in primary care settings where Fibroscan would not be available. In other 
centres, it can be used in combination with Fibroscan to assess fibrotic 
status of liver in patients with Hepatitis B virus / and C infection. 
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ANNEXURES 
 
  
  
 
                                          ABBREVIATIONS 
 
APRI        -  ASPARTATE AMINOTRANSFERASE PLATELET  
   COUNT RATIO  INDEX 
AST          -  ASPARTATE AMINOTRANSFERASE 
ALT          - ALANINE AMINOTRANSFERASE 
HCV         - HEPATITIS C VIRUS 
HBV         - HEPTITIS B VIRUS 
GGTP       - GAMMA GLUTAMYL TRANSPEPTIDASE 
DAA         - DIRECTLY ACTING ANTIVIRALS 
IFN           - INTERFERON ALPHA 
TMA        - TRANSCRIPTION MEDIATED AMPLIFICATION 
EIA          - ENZYME IMMUNOASSAY 
HRQOL   -  HELTH RELATED QUALITY OF LIFE 
HDL        -  HIGH DENSITY LIPOPROTEIN 
HBEAG   - HEPATITIS B ENVELOP ANTIGEN 
HCC        -  HEPATOCELLULAR CARCINOMA 
MHC       -  MAJOR HISTOCOMPTIBILITY COMPLEX 
CTL        -  CYTOTOXIC T LYMPHOCYTE 
 
 
 
                                          
  
PROFORMA 
 
NAME OF THE PATIENT     : 
AGE / SEX            : 
OP/ NUMBER       : 
OCCUPATION       : 
ADDRESS        : 
 
 
CONTACT NUMBER      : 
COMPLAINTS       : 
 
PAST HISTORY       : 
H/o blood transfusions 
H/o previous surgeries 
History of tattooing 
H/o Intravenous drug abuse 
H/o High risk 
behavior/HIV/CKD/ 
Bleeding diathesis/Alcohol 
related liver disease. 
H/o chronic alcoholism 
>30g/day within past 6 
months. 
 
TREATMENT HISTORY : 
  
 
GENERAL EXAMINATION 
Pallor:               Icterus:           Cyanosis:           Clubbing:          
Lymphadenopathy:         Edema: 
 
VITALS 
Pulse Rate:          BP:          Respiratory rate:        Temperature: 
 
SYSTEMIC EXAMINATION 
CARDIOVASCULAR SYSTEM     : 
 
RESPIRATORY SYSTEM         : 
 
ABDOMEN                 : 
 
CENTRAL NERVOUS SYSTEM   : 
                    
 
 
 
 
 
 
 
  
INVESTIGATIONS:   
PLATELET COUNT- 
ASPARTATE AMINOTRANSFERASE - 
APRI SCORE: 
 (ASPARTATE AMINOTRANSFERASE PLATELET RATIO 
INDEX): 
                AST(U/L) / UPPER LIMIT OF AST(U/L)  X 100 
                 PLATELET COUNT(10^9 / L)  
FIBROSCAN VALUE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
THESIS APPROVAL CERTIFICATE 
 
 
 
 
 
  
 
TURNITIN PLAGIARISM 
 
 
 
 
  
  
 
TURNITIN DIGITAL RECEIPT 
 
 
 
 
  
INFORMATIONSHEET 
We are conducting a study on “APRI SCORING AS A 
PREDICTOR OF HEPATIC FIBROSIS IN PATIENTS WITH 
CHRONIC HEPATITIS B AND/OR C INFECTION IN COMPARISON 
WITH FIBROSCAN ” among patients attending Rajiv Gandhi 
Government General Hospital, Chennai and for that your co- operation to 
undergo PLATELET COUNT ,LIVER FUNCTION TEST,FIBROSCAN 
may be valuable to us. 
The purpose of this study is to use APRI scoring as a predictor of 
hepatic fibrosis in patients with chronic Hepatitis B and/or C patients 
with Fibroscan being used as a tool to confirm hepatic fibrosis . 
 
We are selecting certain cases and if you are found eligible, we 
would like  to perform extra tests and special studies which in any way do 
not affect your final report or management. 
The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or presentation 
resulting from the research, no personally identifiable information will be 
shared. 
Taking part in this study is voluntary. You are free to decide 
whether to participate in this study or to withdraw at any time; your 
decision will not result in any loss of benefits to which you are otherwise 
entitled. 
The results of the special study may be intimated to you at the end 
of the study period or during the study if anything is found abnormal 
which may aid in the management or treatment. 
 
 
 
Signature of Investigator Signature/left thumb impression of 
Participant 
 
 
Date : 
Place : 
 
 
  
 
  
  
PATIENT CONSENT FORM 
Study Detail : “APRI SCORING AS A PREDICTOR OF HEPATIC 
FIBROSIS IN PATIENTS WITH CHRONIC 
HEPATITIS B AND/OR C INFECTION IN 
COMPARISON WITH FIBROSCAN ”  
Study Centre : Department of Hepatology, Rajiv Gandhi Government 
General Hospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
Identification 
Number 
:  
Patient may check (☑) these boxes 
I confirm that I have understood the purpose of procedure for the above 
study. I have the opportunity to ask question and all my questions and 
doubts have been answered to my complete satisfaction.  
  
I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time without giving reason, without my legal 
rights being affected.  
I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities will 
not need my permission to look at my health records, both in respect of 
current study and any further research that may be conducted in relation 
to it, even if I withdraw from the study I agree to this access. However, I 
understand that my identity will not be revealed in any information 
released to third parties or published, unless as required under the law. I 
agree not to restrict the use of any data or results that arise from this 
study.  
I agree to take part in the above study and to comply with the instructions 
given during the study and faithfully cooperate with the study team and to 
immediately inform the study staff if I suffer from any deterioration in my 
health or well being or any unexpected or unusual symptoms.  
I hereby consent to participate in this study.  
I hereby give permission to undergo complete clinical examination, and 
necessary investigations.  
 
Signature of Investigator     Signature/thumb impression 
  
Investigator’s Name:            
                                                      Patient’s Name and Address: 
Dr.VIDHYALAKSHMI.C.K. 
  
 
